| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Classified under Biotechnology (Health Care sector), PASG's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 673.8K | $2.77M | - | |
| CEO | 6.5K | - | - | |
| CFO | 5.4K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 8, 2025 | Orbimed Advisors LLC66 | 10% Owner | Sell | 147,024 | $0.70 | $103,305.69 | -2.0% | -50.5% | +39.1% | |
| Dec 27, 2024 | Lynx1 Capital Management LP47 | 10% Owner | Buy | 373,645 | $0.65 | $241,038.39 | +4.2% | -37.1% | -17.4% | |
| Dec 20, 2024 | Orbimed Advisors LLC66 | 10% Owner | Sell | 230,321 | $0.60 | $138,192.60 | -3.0% | -27.9% | -27.3% | |
| Dec 11, 2024 | Orbimed Advisors LLC66 | 10% Owner | Sell | 62,276 | $0.83 | $51,988.04 | -0.8% | -45.5% | -29.6% | |
| Dec 6, 2024 | Orbimed Advisors LLC66 | 10% Owner | Sell | 97,103 | $0.80 | $77,338.46 | -1.2% | -39.4% | -40.6% | |
| Nov 27, 2024 | Lynx1 Capital Management LP47 | 10% Owner | Buy | 456,353 | $0.62 | $284,519.51 | +5.4% | -20.9% | -33.8% | |
| Sep 19, 2024 | Orbimed Advisors LLC66 | 10% Owner | Sell | 39,300 | $0.71 | $27,903.00 | -0.5% | -12.6% | -48.8% | |
| Sep 18, 2024 | Orbimed Advisors LLC66 | 10% Owner | Sell | 200,131 | $0.73 | $146,726.63 | -2.5% | -4.4% | -46.1% | |
| Feb 13, 2024 | Borthwick Kathleen62 | SVP, Interim CFO | Sale+OE | 1,470 | $0.97 | $1,425.90 | -4.9% | +49.5% | -47.5% | |
| Feb 13, 2024 | Forman Mark S | Chief Medical Officer | Sale+OE | 1,638 | $0.97 | $1,588.86 | -3.3% | +49.5% | -47.5% |